The PRADO trial (n=99) tested different surgical and adjuvant therapy strategies based on the pathologic response after neoadjuvant IPI 1mg/kg and NIVO 3mg/kg in stage III melanoma patients (pts)...we report the response and EFS data of PRADO according to the IFN-γ signature and TMB....Pts with a high IFN-γ GES had a higher pRR and MPR rate than pts with a low IFN-γ GES (87% vs 50%, p=0.001 and 77% vs 35%, p<0.001, respectively), and also a higher 2y EFS rate (87% vs 68%, log-rank p=0.015)….Pts with a high TMB were more likely to achieve a pathologic response (pRR 83% vs 58%, p=0.024) and MPR (80% vs 38%, p<0.001)....When combined, the pRR for pts with IFN-γ H/TMB H was 90%, IFN-γ H/TMB L 79%, IFN-γ L/TMB H 67% and IFN-γ L/TMB L 42%. For MPR rates this was 85%, 63%, 67% and 19%, respectively.